GLP-1 Peptide Atlas, by Delfa

← Trials/Trial dossier/NCT07220954

RecruitingPhase 1

A Study to Assess the Relative Bioavailability of Different Subcutaneous Formulations ofAZD6234

A Phase I, Single-Dose, Open-Label, Sequential, Randomised, Crossover Study to Assess the Relative Bioavailability of Different Subcutaneous Formulations of AZD6234 in Participants Living With Overweight or Obesity

Lead sponsor

AstraZeneca

Asset

AZD6234

Subcutaneous · Amylin analog

Listed sites

Recruiting sites

Enrollment

estimated

Study population

Healthy volunteers, Obesity / overweight

Key I/E criteria

•BMI 25-35•Healthy volunteers

Primary endpoints

•Cmax•AUC from time 0 to the time of the last measurable concentration (AUC0-t)•AUC from time 0 extrapolated to infinity (AUC0-inf)

Footprint

Where this trial recruits

Site locations as reported to ClinicalTrials.gov. Site count is not enrollment count; per-site enrollment is not available from source.

Identifiers

Registered as

NCT IDNCT07220954

Org study IDD8750C00008

Timeline

Milestones

Study first posted2025-10-24actual

Study start2025-11-11actual

Last update posted2026-05-18actual

Primary completion2026-09-09estimated

Study completion2027-04-01estimated

Assets

Investigational agents

AZD6234

Study populations

Who this study enrolls

Healthy volunteersObesity / overweight

Eligibility

Who can enroll

Minimum age18 Years

Maximum age55 Years

SexAll

Healthy volunteersAccepted

Inclusion criteria

•Healthy males or non-pregnant, non-lactating females aged 18 to 55 years inclusive

•BMI of 25.0 to 35.0 kg/m2 inclusive and weight ≥50 kg

Exclusion criteria

•History of any clinically important disease or disorder

•History or presence of clinically significant cardiovascular, renal, hepatic, dermatological, respiratory, neurological, psychiatric or gastrointestinal disorder including a history of pancreatitis or gall stones

•Any clinically significant illness, medical/surgical procedure, or trauma within 4 weeks of the planned first dosing day

•Clinically significant abnormal clinical chemistry, haematology, coagulation or urinalysis

•Any clinically significant abnormal findings in vital signs

•Any clinically significant abnormalities on 12-lead ECG

•HbA1c ≥6.5% (≥48 mmol/mol)

•Evidence of renal impairment

•Females who are pregnant or lactating.

•Any participant who has received an amylin analogue containing preparation within the last 30 days or 5 half-lives of the drug (whichever is longer)

•Participants who report to have previously received AZD6234.

•Use of any prescribed or non-prescribed medication

Endpoints (8)

What's being measured

Protocol endpoints and posted registry outcome measures, grouped into outcome categories. Composite endpoints show their component event types. Standard codes (LOINC, SNOMED CT) are shown where available.

Safety / tolerability / PK

8 endpoints

Primary/protocol endpoint

Maximum observed plasma concentration (Cmax)

Time frame:Plasma sample collection from pre- dose to 30 days post final dose

concentration, descriptive

Primary/protocol endpoint

Area under the concentration-time curve from time 0 to the time of the last measurable concentration (AUC0-t)

Time frame:Plasma sample collection from pre- dose to 30 days post final dose

concentration, descriptive

Primary/protocol endpoint

Area under the concentration-time curve from time 0 extrapolated to infinity (AUC0-inf)

Time frame:Plasma sample collection from pre- dose to 30 days post final dose

concentration, descriptive

Secondary/protocol endpoint

Number of subjects with adverse events (AEs)/serious AEs (SAEs), and change from baseline for vital signs, electrocardiograms (ECGs), and laboratory safety tests

Time frame:Through study duration, approximately 19 weeks

change from baseline, event

Secondary/protocol endpoint

Time of maximum observed plasma concentration (tmax)

Time frame:Plasma sample collection from pre- dose to 30 days post final dose

concentration, descriptive

Secondary/protocol endpoint

Terminal elimination half-life (t1/2)

Time frame:Plasma sample collection from pre- dose to 30 days post final dose

concentration, descriptive

Secondary/protocol endpoint

Total body clearance calculated after a single extravascular administration where F (fraction of dose bioavailable) is unknown (CL/F)

Time frame:Plasma sample collection from pre- dose to 30 days post final dose

concentration, descriptive

Secondary/protocol endpoint

Volume of distribution based on the terminal phase calculated using AUC0-inf after a single extravascular administration where F (fraction of dose bioavailable) is unknown (Vz/F)

Time frame:Plasma sample collection from pre- dose to 30 days post final dose

ratio, event

Provenance

Sources

Trial identity, design, statusClinicalTrials.gov API v2

Snapshot dateJuly 1, 2026

Endpoint classificationDelfa endpoint taxonomy v2 (May 13, 2026)

Results tableno registry results posted yet

Trial facts come from public ClinicalTrials.gov records. Endpoint categories are Delfa's classification of those records, not a ClinicalTrials.gov field. All figures reflect the July 1, 2026 snapshot.